Compare NUTX & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUTX | PMN |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 729.5M | 23.5M |
| IPO Year | N/A | N/A |
| Metric | NUTX | PMN |
|---|---|---|
| Price | $168.10 | $8.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $252.50 | $72.67 |
| AVG Volume (30 Days) | ★ 181.0K | 33.1K |
| Earning Date | 11-19-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 17.98 | N/A |
| Revenue | ★ $981,195,633.00 | N/A |
| Revenue This Year | $104.36 | N/A |
| Revenue Next Year | $4.10 | N/A |
| P/E Ratio | $9.35 | ★ N/A |
| Revenue Growth | ★ 236.03 | N/A |
| 52 Week Low | $28.82 | $6.27 |
| 52 Week High | $193.00 | $39.75 |
| Indicator | NUTX | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 56.25 | 70.99 |
| Support Level | $156.15 | $8.00 |
| Resistance Level | $180.76 | $9.15 |
| Average True Range (ATR) | 14.18 | 0.58 |
| MACD | -1.32 | -0.26 |
| Stochastic Oscillator | 37.73 | 44.44 |
Nutex Health Inc is healthcare services and operations company with 20 hospital facilities in eight states (hospital division), and a primary care-centric, risk-bearing population health management division. The hospital division implements and operates healthcare models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management division owns and operates provider networks such as independent physician associations (IPAs) and offers a cloud-based proprietary technology platform to IPAs that aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.